ZYMEWORKS INC. (ZYME) Operating Margin
- Operating margin · 12 months: Value -418.99%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -418.99% | Operating income / revenue. Period ending 2026-06-30. $-155.56M ÷ $37.13M × 100 ≈ -418.99% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -155.56M USD | Operating Income (Loss) |
| Revenue | 37.13M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-155.56M | $37.13M | (m) | (m) | (m) | -418.99% |
| 2026-03-31 | $-114.05M | $81.26M | (m) | (m) | (m) | -140.35% |
| 2025-12-31 | $-92.55M | $105.97M | (m) | (m) | (m) | -87.34% |
| 2025-09-30 | $-70.61M | $134.48M | (m) | (m) | (m) | -52.51% |
| 2025-06-30 | $-82.71M | $122.87M | (m) | (m) | (m) | -67.32% |
| 2025-03-31 | $-124.92M | $93.38M | (m) | (m) | (m) | -133.77% |
| 2024-12-31 | $-137.11M | $76.30M | (m) | (m) | (m) | -179.69% |
| 2024-09-30 | $-138.31M | $62.20M | (m) | (m) | (m) | -222.37% |
| 2024-06-30 | $-137.35M | $62.70M | (m) | (m) | (m) | -219.04% |
| 2024-03-31 | $-148.57M | $50.46M | (m) | $129.75M | (m) | -294.42% |
| 2023-12-31 | $-138.05M | $76.01M | (m) | $143.62M | (m) | -181.62% |
| 2023-09-30 | $204.76M | $461.58M | (m) | $171.06M | (m) | 44.36% |
| 2023-06-30 | $187.64M | $447.70M | (m) | $175.38M | (m) | 41.91% |
| 2023-03-31 | $175.93M | $446.14M | (m) | $192.00M | (m) | 39.43% |
| 2022-12-31 | $130.53M | $412.48M | (m) | $208.60M | (m) | 31.64% |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-215.63M | $26.68M | (m) | $199.75M | (m) | -808.22% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-187.47M | $38.95M | (m) | $171.20M | (m) | -481.29% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |